Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 13;10(11):435.
doi: 10.3390/cancers10110435.

Next-Generation Service Delivery: A Scoping Review of Patient Outcomes Associated with Alternative Models of Genetic Counseling and Genetic Testing for Hereditary Cancer

Affiliations

Next-Generation Service Delivery: A Scoping Review of Patient Outcomes Associated with Alternative Models of Genetic Counseling and Genetic Testing for Hereditary Cancer

Jeanna M McCuaig et al. Cancers (Basel). .

Abstract

The combination of increased referral for genetic testing and the current shortage of genetic counselors has necessitated the development and implementation of alternative models of genetic counseling and testing for hereditary cancer assessment. The purpose of this scoping review is to provide an overview of the patient outcomes that are associated with alternative models of genetic testing and genetic counseling for hereditary cancer, including germline-only and tumor testing models. Seven databases were searched, selecting studies that were: (1) full-text articles published ≥2007 or conference abstracts published ≥2015, and (2) assessing patient outcomes of an alternative model of genetic counseling or testing. A total of 79 publications were included for review and synthesis. Data-charting was completed using a data-charting form that was developed by the study team for this review. Seven alternative models were identified, including four models that involved a genetic counselor: telephone, telegenic, group, and embedded genetic counseling models; and three models that did not: mainstreaming, direct, and tumor-first genetic testing models. Overall, these models may be an acceptable alternative to traditional models on knowledge, patient satisfaction, psychosocial measures, and the uptake of genetic testing; however, particular populations may be better served by traditional in-person genetic counseling. As precision medicine initiatives continue to advance, institutions should consider the implementation of new models of genetic service delivery, utilizing a model that will best serve the needs of their unique patient populations.

Keywords: BRCA; genetic counseling; genetic service delivery; genetic testing; hereditary cancer; patient outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Prisma Flow Diagram.

References

    1. Evans D.G., Barwell J., Eccles D.M., Collins A., Izatt L., Jacobs C., Donaldson A., Brady A.F., Cuthbert A., Harrison R., et al. The Angelina Jolie effect: How high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 2014;16:442. doi: 10.1186/s13058-014-0442-6. - DOI - PMC - PubMed
    1. Raphael J., Verma S., Hewitt P., Eisen A. The Impact of Angelina Jolie (AJ)’s Story on Genetic Referral and Testing at an Academic Cancer Centre in Canada. J. Genet. Couns. 2016;25:1309–1316. doi: 10.1007/s10897-016-9973-6. - DOI - PubMed
    1. Buchtel K.M., Vogel Postula K.J., Weiss S., Williams C., Pineda M., Weissman S.M. FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices. J. Genet. Couns. 2018;27:131–139. doi: 10.1007/s10897-017-0130-7. - DOI - PubMed
    1. Zhang S., Royer R., Li S., McLaughlin J.R., Rosen B., Risch H.A., Fan I., Bradley L., Shaw P.A., Narod S.A. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol. Oncol. 2011;121:353–357. doi: 10.1016/j.ygyno.2011.01.020. - DOI - PubMed
    1. Harter P., Hauke J., Heitz F., Reuss A., Kommoss S., Marmé F., Heimbach A., Prieske K., Richters L., Burges A., et al. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1) PLoS ONE. 2017;12:e0186043. doi: 10.1371/journal.pone.0186043. - DOI - PMC - PubMed

Publication types